Table 2 Subgroup analyses of 2LCTX benefit in aBTC Table 2.

From: Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

 

Hazard ratio

95%CI

Interaction p-value

ECOG: 0

0.89

0.24–3.39

0.237

ECOG: 1–2

0.37

0.13–1.08

Synchronous aBTC

0.30

0.07–1.20

0.524

Metachronous aBTC

0.45

0.16–1.24

No response during 1stline CTX

0.41

0.16–1.04

0.159

Response during 1stline CTX

0.24

0.03–1.73

Bilirubin ≤ 50th percentile

0.40

0.13–1.25

0.813

Bilirubin > 50th percentile

0.58

0.24–1.36

C-reactive protein ≤ 50th percentile

0.54

0.15–1.88

0.349

C-reactive protein > 50th percentile

0.32

0.15–0.70

aBTC: Gallbladder

0.05

0.01–0.39

0.020

aBTC: Intrahepatic CCC

0.64

0.22–1.88

aBTC: Others

1.08

0.28–4.24

  1. Subgroup analyses of 2LCTX benefit in aBTC. Hazard ratios and interaction p-values were derived from IPTW-weighted Cox regression models of overall survival. Abbreviations: 2LCTX – 2nd-line chemotherapy, aBTC – Advanced biliary tract cancer, 95%CI – 95% confidence interval, ECOG – Eastern Cooperative Oncology Group performance status, CTX - chemotherapy
Back to article page